In the last trading session, 1.04 million IGC Pharma Inc (AMEX:IGC) shares changed hands as the company’s beta touched 1.37. With the company’s per share price at $0.32 changed hands at -$0.01 or -4.42% during last session, the market valuation stood at $25.50M. IGC’s last price was a discount, traded about -184.38% off its 52-week high of $0.91. The share price had its 52-week low at $0.26, which suggests the last value was 18.75% up since then. When we look at IGC Pharma Inc’s average trading volume, we note the 10-day average is 0.6 million shares, with the 3-month average coming to 404.00K.
Analysts gave the IGC Pharma Inc (IGC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IGC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. IGC Pharma Inc’s EPS for the current quarter is expected to be -0.02.
IGC Pharma Inc (AMEX:IGC) trade information
Instantly IGC was in red as seen at the end of in last trading. With action -1.90%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -4.76%, with the 5-day performance at -1.90% in the red. However, in the 30-day time frame, IGC Pharma Inc (AMEX:IGC) is 4.64% up. Looking at the short shares, we see there were 0.94 million shares sold at short interest cover period of 2.53 days.
IGC Pharma Inc (IGC) estimates and forecasts
Year-over-year growth is forecast to reach -7.36% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 305k. 1 analysts are of the opinion that IGC Pharma Inc’s revenue for the current quarter will be 326k. The company’s revenue for the corresponding quarters a year ago was 295k and 272k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3.39%. The estimates for the next quarter sales put growth at 19.85%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.79%. The 2025 estimates are for IGC Pharma Inc earnings to increase by 54.55%, but the outlook for the next 5-year period is at 18.29% per year.
IGC Dividends
IGC Pharma Inc is expected to release its next quarterly earnings report on 2025-Feb-13.
IGC Pharma Inc (AMEX:IGC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.52% of IGC Pharma Inc shares while 20.91% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 22.61%. There are 20.91% institutions holding the IGC Pharma Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 1.1961% of the shares, roughly 0.7 million IGC shares worth $0.31 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.0965% or 0.65 million shares worth $0.28 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . With 630.22 shares estimated at $0.2 million under it, the former controlled 1.59% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.96% of the shares, roughly 381.64 shares worth around $0.12 million.
